HEIDELBERG PHARMA
Live / Registered — Registered (as of 31 Mar 2020)
What this means for you
Registered since 31 Mar 2020. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 88064933
- Registration number
- 6021542
- Mark type
- Design + words
- Filed
- 03 Aug 2018
- Published for opposition
- 14 Jan 2020
- Registered
- 31 Mar 2020
- Attorney of record
- Todd A. Sullivan
Goods and services
- Class 001 — Chemicals: Biochemicals, namely, monoclonal antibodies for in vitro scientific or research use
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of immuno oncological disorders, namely, cancer; pharmaceuticals for cancer therapy; chemico-pharmaceutical preparations for cancer therapies; pharmaceutical preparations and substances for use in the treatment of cancer; chemical preparations for pharmaceutical purposes, namely, for the treatment of cancer; pharmaceutical preparations for human use, namely, for the treatment of cancer; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in chemotherapy; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for use in oncology; diagnostic preparations for medical purposes; diagnostic agents for pharmaceutical use; diagnostic agents for medical use; clinical diagnostic reagents; diagnostic chemical reagents for medical use; anti-cancer drugs; compounds for treating cancer; anti-cancer preparations; anti-cancer preparations of chemical origin; biopharmaceuticals for the treatment of cancer; pharmaceutical preparations and substances for the prevention of cancer; chemotherapeutics; diagnostic kits consisting primarily of monoclonal antibodies for use in disease testing
- Class 042 — Scientific and technological services: Pharmaceutical research services; medical and pharmacological research services; pharmaceutical products development; development of pharmaceutical preparations and medicines; consultancy relating to pharmaceutical research and development; scientific research; medical research; biomedical research services; research relating to biotechnology; research on the subject of pharmaceuticals; consultancy relating to research in the field of pharmacogenetics; research and development in the pharmaceutical and biotechnology fields; research and development in the field of diagnostic preparations; research and development in the field of biotechnology; research and development for the pharmaceutical industry; research and development services in the field of antibody technology; research and development services in the field of antibodies; laboratory services relating to the production of monoclonal antibodies
- Class 044 — Medical, beauty and agricultural services: Pharmaceutical advice; pharmaceutical services, namely, providing pharmaceutical advice and consultation and dispensing drugs to patients with cancer; consultancy and medical information services relating to pharmaceutical products
Owner
- Heidelberg Pharma AG, Ladenburg, DE
- Heidelberg Pharma AG, Ladenburg, DE
- Heidelberg Pharma AG, Ladenburg, DE
Prosecution history
- 31 Mar 2025 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 04 Feb 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 04 Feb 2025 — TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
- 04 Feb 2025 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 04 Feb 2025 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 04 Feb 2025 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 04 Feb 2025 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 05 Jan 2021 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 05 Jan 2021 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 05 Jan 2021 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 05 Jan 2021 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 05 Jan 2021 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 31 Mar 2020 — REGISTERED-PRINCIPAL REGISTER
- 14 Jan 2020 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 14 Jan 2020 — PUBLISHED FOR OPPOSITION